William Walsh

A mammalian cell cycle checkpoint pathway utilizing p53 and GADD45 is defective in ataxia-telangiectasia

Michael B. Kastan, Qimin Zhan, Wafik S. El‐Deiry et al. · Cell · 1992 · 3.1K citations

Genome Instability, Cell Regulation, Cell Death +5

Wild-type p53 is a cell cycle checkpoint determinant following irradiation.

Steven J. Kuerbitz, Beverly Plunkett, William Walsh et al. · Proceedings of the National Academy of Sciences · 1992 · 1.9K citations · Full text

Tumor Biology, Genome Instability, Wild-type P53 +15

Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study

Ezra E.W. Cohen, Denis Soulières, Christophe Le Tourneau et al. · The Lancet · 2018 · 1.6K citations · Full text

Medicine, Pathology, Head And Neck Cancer +5

Pembrolizumab plus concurrent chemoradiotherapy versus placebo plus concurrent chemoradiotherapy in patients with locally advanced squamous cell carcinoma of the head and neck (KEYNOTE-412): a randomised, double-blind, phase 3 trial

Jean‐Pascal Machiels, Yungan Tao, Lisa Licitra et al. · The Lancet Oncology · 2024 · 174 citations · Full text

Concurrent Chemoradiotherapy, Neoadjuvant Therapy, Squamous Cell Carcinoma +6

Phase II Study of Obatoclax Mesylate (GX15-070), a Small-Molecule BCL-2 Family Antagonist, for Patients With Myelofibrosis

Sameer A. Parikh, Hagop M. Kantarjian, Aaron D. Schimmer et al. · Clinical Lymphoma Myeloma & Leukemia · 2010 · 85 citations

Inflammation, Molecular Pharmacology, Hematological Malignancy +8